These results suggested that the accelerated course of systemic inflammation could be mediated by an enhanced IL-6 synthesis and that this disturbed IL-6 production in T cells of MS patients could be responsible for their in vivo Treg resistance. The gene discussed is IL6; the disease is myeloid sarcoma.